scholarly journals Evaluation of non-small cell lung cancer treatment strategies in a region of China with low-risk for COVID-19

2020 ◽  
Author(s):  
Minhao Yu ◽  
Yalin Cheng
Keyword(s):  
Lung Cancer ◽  
Cancer Progression ◽  
Late Stage ◽  
Early Stage ◽  
Treatment Strategies ◽  
Small Cell ◽  
Low Risk ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group

Abstract Purpose This study analyzed the morbidity and mortality associated with non-small cell lung cancer (NSCLC) and evaluated treatment strategies for it in a low-risk area of COVID-19 in China. Materials and methods: We selected patients admitted to Sichuan Science City Hospital from September 2019 to February 2020 and divided them into experimental and control groups. The treatment strategy was evaluated by patients’ prognosis. Results: 9,010 patients were hospitalized. The total morbidity was 0.699%, of which 0.504% was observed in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.999/103, of which 0.630/103 was observed in the control group and 1.413/103 in the experimental group (P=0.322). Therapy discontinuation and cancer progression in the experimental group were significantly higher than the control group (P＜0.001, P=0.007). The treatment methods and prognosis were not significantly different for early-stage patients between the two groups. Late-stage patients in the experimental group experienced significantly lower percentages of non-surgical treatments (P＜0.001), higher percentages of discontinued therapies (P＜0.001), lower percentages for prognosis of wellness (P＜0.001), and higher percentages of cancer progression (P＜0.001) than the control group. Conclusion: NSCLC exhibited significantly higher morbidities during the COVID-19 pandemic. The mortality in the experimental group was slightly higher than the control group, while the difference in cancer progression was significant. It is feasible to perform surgery for early-stage NSCLC patients, and treatment should not be suspended for late-stage patients in regions with low-risk for COVID-19 infection.

scholarly journals Evaluating Treatment strategies for Non-small Cell Lung Cancer during COVID-19: A Propensity Scores Matching Analysis

2021 ◽  
Author(s):  
Minhao Yu ◽  
Yalin Cheng
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Cell Lung Cancer ◽  
Late Stage ◽  
Propensity Scores ◽  
Early Stage ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung

Abstract Background We had different understanding of treatment strategies to which we preferred conduct surgery for early-stage patients and delay treatment for late-stage non-small cell lung cancer patients at beginning of the COVID-19 pandemic. However, as we learned more about other guidelines, we were not sure whether our strategies have caused adverse results. Methods We divided patients hospitalized from September 2019 to February 2020 into experimental and control groups, and evaluated treatment strategies by patients’ prognosis. Propensity scores matching was used to adjust selection bias. Results Therapy discontinuation in the experimental group were significantly higher than the control group (P༜0.001). The differences of cancer progression and the number of deaths between the two groups were not significant (P = 0.376, 0.128, respectively). There were significant differences in non-surgical treatment and discontinued therapy for late-stage patients (P༜0.001, ༜0.001, respectively), while the differences of surgical treatment and therapy discontinuance for early-stage patients were not significant (P = 0.243, 0.243, respectively). The cancer progression and death toll differences in both early and late stage between the two groups were not significant (P = 0.608, 0.489, 0.197, 0.197, respectively). Multivariate analysis revealed therapy discontinuation did not predicted progress-free survival independently (hazard ratio = 1.007, 95% confidence interval: 0.653–1.552, P = 0.976). Conclusions For patients in regions with low risk for COVID-19 infections, surgery should not be delayed for early-stage patients if the hospital has adequate medical resources and strict testing and prevention measures are utilized. Delaying treatment less than three months can not significantly impact the prognosis of late-stage non-small cell lung cancer patients.

scholarly journals The morbidity and mortality of non-small cell lung cancer in low risk areas of the COVID-19

2020 ◽  
Author(s):  
Minhao Yu ◽  
Yalin Cheng
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Low Risk ◽  
Control Group ◽  
Small Cell Lung ◽  
Risk Areas ◽  
Experimental Group

Abstract Objective: To analyze the morbidity and mortality of non-small cell lung cancer and evaluate treatment strategies for non-small cell lung cancer patients in low-risk areas of the COVID-19.Materials and methods: We selected patients in the hospital in Sichuan Science City Hospital from September 2019 to February 2020 as research subjects and divided them into experimental and control groups. The evaluation of treatment strategy was based on morbidity and mortality.Results: There were 9010 patients hospitalized. The total morbidity was 0.699%, which was 0.504% in the control group and 0.991% in the experimental group (P=0.024). The total mortality was 0.887 /103, which was 0.840/103 in the control group (4/4764) and 0.942/103 in the experimental group (P=0.998). The patients discontinued therapy or follow-up and cancer progression in the experimental group was significantly higher than that in the control group (P＜0.001, =0.007). Most of the discontinued and progressive cancer patients were elderly and in late stage.Conclusion: The morbidity of NSCLC during the COVID-19 pandemic was significantly high. The mortality in the experimental group was slightly higher than that in the control group, while the difference in cancer progression was significant. It is practicable to perform surgery for early-stage NSCLC patients and undesirable to suspend treatment for late-stage patients in low-risk areas.

scholarly journals Therapeutic effects of Kanglaite injection combined with chemotherapy on advanced non-small cell lung cancer (NSCLC).

2018 ◽  
Vol 2 (4) ◽  
Author(s):  
Zhaoji Luan
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Late Stage ◽  
Effective Rate ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Total Treatment ◽  
Experimental Group

AbstractObjective: To study the therapeutic effect of Kanglaite injection combined with chemotherapy in the treatment of late stage non-small cell lung cancer (NSCLC), and also to observe the effect of the combination treatment on immune function. Methodology: 92 patients with advaned stage of non-small cell lung cancer who admitted to First Hospital of ZiBo city hospital from May 2017 to October 2018 were randomly divided into experimental group and control group, with 46 cases respectively. The control group was treated with chemotherapy only while the experimental group was treated with Kanglaite injection combined with chemotherapy which was the basic treatment for patients, and the total treatment effective rate, adverse reaction rate and immune index of the treatments on two groups were compared. Result: The total treatment effective rate of the experimental group was 80.43%, which was significantly higher than that of the control group, which was 63.04%. The incidence of adverse reactions in the experimental group was 36.96%, which was lower than that of the control group (78.26%). The immune indexes of the experimental group (CD3+, CD4+, IgG, IgA) were better than that of the control group, respectively. The differences between the two groups were statistically significant (P<0.05).Conclusion: During the chemotherapy of late stage or advanced non-small cell lung cancer, the addition use of Kanglaite injection has a significant effect on improving tumor control and reducing the side effects of chemotherapy, and helps to improve the immune function of patients, thus it is worth promoting.

scholarly journals MINI01.06: Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non–Small Cell Lung Cancer Progression and Clinical Outcome

2016 ◽  
Vol 11 (11) ◽  
pp. S259-S260 ◽  
Author(s):  
Imad Tarhoni ◽  
Cristina Fhied ◽  
Ravi Pithadia ◽  
Christopher W. Seder ◽  
Sanjib Basu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Outcome ◽  
Small Cell Lung Cancer ◽  
Cancer Progression ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

Investigating gene expression profile of non-small cell lung cancer

Open Medicine ◽  
2011 ◽  
Vol 6 (5) ◽  
pp. 608-615
Author(s):  
Tõnu Vooder ◽  
Andres Metspalu
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Survival Rate ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Treatment Strategies ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

AbstractLung cancer is mainly a lifestyle-associated disease with poor prognosis and the lowest five year survival rate of all types of cancer. Lung cancers are divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Surgical treatment is generally indicated in cases of early stage NSCLC, and those patients treated with radical and aggressive surgery have a somewhat better survival rate. The main problems with lung cancer treatment are due to late diagnosis, rapidly developing drug resistance and side effects of the treatment that are experienced by almost all patients. The next step for distinguishing histologically complicated lung cancers and determining optimal treatment strategies is gene expression analysis. Supported by gene expression data, it is possible to prognosticate the course of the disease.

scholarly journals Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Jingyao Li ◽  
Yang Qiu ◽  
Junxiu Yi ◽  
Xi Liu ◽  
Shixin Zhang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mrna Expression ◽  
Chemotherapy Regimen ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group ◽  
Selection Of

Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( P > 0.05 ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, P = 0.0025 ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( P = 0.025 ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( P = 0.0039 ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.

scholarly journals Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer

2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Xiaoyan Liang ◽  
Zhangfeng Wei
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Immune Function ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Serum Tumor Markers ◽  
Experimental Group

Objective: To evaluate the effect of sintilimab combined with chemotherapy on tumor markers and immune function in advanced non-small cell lung cancer. Methods: The study was conducted at Xi’an Medical University, China. The 120 patients with advanced NSCLC who were treated in our hospital from January 2016 to January 2020 were randomly divided into two groups, with 60 cases in each group. Patients in the control group received conventional GP chemotherapy, while those in the experimental group received intravenous injection of sindilimab on the basis of conventional GP chemotherapy. The changes of serum tumor markers CYFRA211, CEA, CA125 and T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ in the two groups prior to and after treatment were compared and analyzed. At the same time, the clinical efficacy at six months was compared between the two groups. Results: The serum tumor markers CYFRA211, CEA and CA125 in the two groups after treatment were lower than those before treatment, and the difference was statistically significant (P=0.00). Specifically, the above-mentioned markers in the experimental group decreased more significantly than those in the control group, and the difference was statistically significant (CYFRA211, CA125, p=0.00; CEA, p=0.01; the levels of CD3+ and CD4+ in the experimental group were higher than those in the control group after treatment, with statistical significance (CD3+, p=0.00; CD4+, p=0.01)). No significant change can be seen in CD8+ (p=0.14), and the level of CD4+/CD8+ in the experimental group was higher than that in the control group, with a significant difference (p=0.02). The complete remission rate (CR) was 22% in the experimental group and 8% in the control group (P=0.04), which was statistically significant. The progress rate (PD) of the experimental group was significantly lower than that of the control group, with statistical significance (p=0.02). The overall response rate (RR) of the experimental group was more advantageous than that of the control group, with a statistically significant difference (p=0.01). Conclusion: Compared with chemotherapy alone, significant therapeutic effects can be obtained in the treatment of advanced non-small cell lung cancer with sintilimab combined with chemotherapy. With this combination regimen, the level of serum tumor markers can be significantly reduced, the cellular immune function of patients can be improved, with the overall response rate of treatment increased, and the risk of progressive disease of patients reduced. doi: https://doi.org/10.12669/pjms.37.4.3820 How to cite this:Liang X, Wei Z. Effect of Sintilimab combined with Chemotherapy on Tumor Markers and Immune Function of advanced non-small cell lung cancer. Pak J Med Sci. 2021;37(4):---------. doi: https://doi.org/10.12669/pjms.37.4.3820 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals A randomized, double-blind, placebo-controlled study of B-cell lymphoma 2 homology 3 mimetic gossypol combined with docetaxel and cisplatin for advanced non-small cell lung cancer with high expression of apurinic/apyrimidinic endonuclease 1

2020 ◽  
Vol 38 (6) ◽  
pp. 1862-1871
Author(s):  
Yuxiao Wang ◽  
Xuemei Li ◽  
Liang Zhang ◽  
Mengxia Li ◽  
Nan Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Response Rate ◽  
B Cell Lymphoma ◽  
Small Cell ◽  
Controlled Study ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group

Summary Background Overexpression of apurinic/apyrimidinic endonuclease 1 (APE1) is an important cause of poor chemotherapeutic efficacy in advanced non-small cell lung cancer (NSCLC) patients. Gossypol, a new inhibitor of APE1, in combination with docetaxel and cisplatin is believed to improve the efficacy of chemotherapy for advanced NSCLC with high APE1 expression. Methods Sixty-two patients were randomly assigned to two groups. Thirty-one patients in the experimental group received 75 mg/m2 docetaxel and 75 mg/m2 cisplatin on day 1 with gossypol administered at 20 mg once daily on days 1 to 14 every 21 days. The control group received placebo with the same docetaxel and cisplatin regimen. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), response rate, and toxicity. Results There were no significant differences in PFS and OS between the experimental group and the control group. The median PFS (mPFS) in the experimental and control groups was 7.43 and 4.9 months, respectively (HR = 0.54; p = 0.06), and the median OS (mOS) was 18.37 and 14.7 months, respectively (HR = 0.68; p = 0.27). No significant differences in response rate and serious adverse events were found between the groups. Conclusion The experimental group had a better mPFS and mOS than did the control group, though no significant difference was observed. Because the regimen of gossypol combined with docetaxel and cisplatin was well tolerated, future studies with larger sample sizes should be performed.

scholarly journals Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Yu-jie Cui ◽  
Jia Liu ◽  
Miao-miao Liu ◽  
Hong-zhen Zhang
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Effect ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group

Objectives: To evaluate the clinical effect of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Eighty patients with advanced NSCLC treated in Hebei General Hospital from January 2017 to July 2020 were randomly divided into two groups: the experimental group and the control group, each with 40 cases. Patients in the control group were treated with conventional paclitaxel combined with cisplatin chemotherapy, while patients in the experimental group were treated with apatinib mesylate tablets based on the treatment of the control group. After treatment, tumor efficacy evaluation was conducted on all patients every two cycles, and the therapeutic effect, adverse drug reactions, improvement of quality-of-life scores prior to and after treatment, and changes of indicators such as tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 153(CA153) were compared and analyzed between the two groups.  Results: The total effective rate of the experimental group was 67.5%, which was significantly better than the 45% of the control group (p=0.04); The incidence of adverse drug reactions in the experimental group was 25%, while that in the control group was 37.5%, with no significant difference (p=0.23); Moreover, the improvement rate of quality of life scores in the experimental group was significantly higher than that in the control group (p=0.03), and the levels of CEA and CA153 in the experimental group were significantly lower after treatment than those in the control group, with a statistically significant difference (p=0.01). Conclusion: Apatinib combined with conventional chemotherapy is effective in the treatment of advanced non-small cell lung cancer, the quality of life can be significantly improved, tumor markers can be significantly reduced, and adverse reactions will not be significantly increased. doi: https://doi.org/10.12669/pjms.37.4.4066 How to cite this:Cui Y, Liu J, Liu M, Zhang H. Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci. 2021;37(4):---------.   doi: https://doi.org/10.12669/pjms.37.4.4066 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document